Episode Details

Ever wonder how the CBD model actually works once cannabis rescheduling is implemented? Or how real-world medical evidence is finally starting to tell a clearer story around cannabinoids? And finally, what might be one of the biggest earnings prints yet from a major cannabis company — who is it, and why does it matter?We’re covering all of this in today’s episode.Segment One: Pulak Sharma, co-founder and CEO of Kazmira Therapeutics, will join us to break down how CBD coverage, prescribing, and delivery could realistically take shape in a post-rescheduling environment. We’ll also dig into Kazmira’s January 20 press release announcing the launch of the first cannabis-grade dispensary in Colorado, and what that signals about where pharmaceutical-grade cannabinoid distribution is heading in the U.S.Segment Two: High Tide (TSX: HITI | NASDAQ: HITI) CEO Raj Grover joins us following what may be the strongest earnings report in the company’s history — record revenue, positive free cash flow, expanding margins, and a loyalty-driven retail model showing real operating leverage.Policy. Proof. Performance.All in one episode.#TradeToBlack #CannabisInvesting #CBDPolicy#MedicalCannabis #CannabisNews #CannabisStocks#EarningsSeason #CannabisIndustry#CannabisReform #FlowhubWant to see more Cannabis Reform videos?🎬    • Why Washington Still Bans Homegrown Cannab...  🎬    • Who’s Trying to Undo Legal Cannabis? | TDR...  🎬    • Why Giving Trump a Cannabis License Could ...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:

Listen Now